Login to Your Account

Financings Roundup

mRNA Cancer Vaccines Score CureVac $105M in Financing

By Cormac Sheridan
Staff Writer

Wednesday, September 19, 2012
CureVac GmbH closed what will in all likelihood go down as the largest private equity round in European biotechnology this year, an €80 million (US$104.9 million) investment from dievini Hopp BioTech Holding GmbH & Co. KG, which will enable it to take forward two mRNA-based therapeutic cancer vaccines, in clinical development for prostate cancer and non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription